A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper [0.03%]
急性肝衰竭与慢性肝病重叠患者的重症监护管理的全球共识：亚太肝脏研究学会北京声明文件(APASL)
Tao Chen,Ashok Choudhury,Wei Liu et al.
Tao Chen et al.
Background and aims: Acute-on-chronic liver failure (ACLF) is a severe syndrome in patients with chronic liver disease, marked by rapid multi-organ failure and high short-term mortality. Managing ACLF requires intensive c...
Histomorphometry indicates distinct contributions of myofibroblast activation and sinusoidal capillarization to portal hypertension [0.03%]
组织形态计量学表明肌纤维活化和血窦毛细管化在门静脉高压症中发挥不同的作用
Thomas Sorz-Nechay,Benedikt S Hofer,Philipp Königshofer et al.
Thomas Sorz-Nechay et al.
Background and aims: Portal hypertension (PH) is a severe consequence of cirrhosis and the primary driver of hepatic decompensation. We aimed to investigate the link between histological myofibroblast activation (alpha-sm...
GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials [0.03%]
葡萄糖依赖性促胰岛素多肽受体激动剂治疗与代谢紊乱相关的非酒精性脂肪性肝炎：系统评价和 meta 分析
Shi-Ping Sun,Chen-Xi Wang,Ming-Kai Yuan et al.
Shi-Ping Sun et al.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with unmet clinical treatment needs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic ...
Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography [0.03%]
痛风独立于肥胖与肝脏隐源性纤维炎有关：基于多队列的MRI-cT1和弹性成像研究
Yixian Mei,Weiqi Cai,Qiming Huang et al.
Yixian Mei et al.
Background and aims: Gout frequently co-occurs with steatotic liver disease, but its direct hepatotoxic effect beyond obesity remains contentious. We aimed to elucidate the independent association between gout and hepatic...
Plasma metabolic signatures of healthy dietary patterns and risk of metabolic dysfunction-associated steatotic liver disease and cirrhosis [0.03%]
健康饮食模式的血浆代谢标志物与代谢功能紊乱相关脂肪性肝病和肝硬化的风险的关系
Shijia Wang,Yingxin Liao,Zhijun Xue et al.
Shijia Wang et al.
Background: The underlying mechanisms of the associations between dietary patterns and liver disease remain unclear. We aimed to identify metabolic signatures (MSs) reflecting adherence to ten healthy dietary patterns and...
Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis [0.03%]
亚洲肌少症工作组2019年和2025年的肌少症定义在肝硬化患者中的预后性能评估
Kei Endo,Keisuke Kakisaka,Tokio Sasaki et al.
Kei Endo et al.
Background/purpose of the study: The Asian Working Group for Sarcopenia (AWGS) updated its criteria in 2025, adding a body mass index (BMI)-adjusted muscle index (ASM/BMI) to the conventional skeletal muscle index (SMI). ...
Epidemiology of primary sclerosing cholangitis in general and IBD populations: a systematic review and meta-analysis [0.03%]
原发性硬化性胆管炎的一般和炎症性肠病人群流行病学：系统回顾和元分析
Glenn Jun Kit Ho,Asvin Selvakumar,Lucas Yang Yuxu Yeo et al.
Glenn Jun Kit Ho et al.
Background & aims: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver condition that is closely associated with inflammatory bowel disease (IBD). PSC is associated with substantial long-term hepatobiliary...
Neutrophil extracellular traps drive cholangiocyte injury via ZNF709-TP53-MDM2 pathway in primary biliary cholangitis [0.03%]
中性粒细胞胞外诱捕网通过ZNF709-TP53-MDM2通路驱动原发性胆汁性肝硬化胆管上皮细胞损伤
Mingxin Su,Zhenfeng Tian,Miao Yu et al.
Mingxin Su et al.
Background: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease in which many patients respond inadequately to ursodeoxycholic acid (UDCA) and may progress to liver failure. Although research on PBC ha...
New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study [0.03%]
一项全国队列研究：新的口服抗凝药物与乙型肝炎、丙型肝炎和酒精性肝病患者的肝细胞癌之间的关系
Yu-Wen Su,Yu-Hsuan Pai,Yao-Min Hung et al.
Yu-Wen Su et al.
Background: Coagulation pathways are increasingly recognized as an influencer of tumor development. Experimental evidence suggests that commonly used anticoagulants, including warfarin and non-vitamin K oral anticoagulant...
Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma [0.03%]
外周血cfDNA CD86甲基化与阿特珠单抗-贝伐珠单抗治疗肝细胞癌疗效的相关性研究
Akimitsu Meno,Masatsugu Ohara,Goki Suda et al.
Akimitsu Meno et al.
Background: /purpose. Although atezolizumab-bevacizumab is approved for unresectable hepatocellular carcinoma (HCC), only a subset of patients attains a durable response (DR). Non-invasive predictors of long-term benefit ...